267 related articles for article (PubMed ID: 11697844)
1. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte PF; Del Tacca M
Ann Oncol; 2001 Sep; 12(9):1301-6. PubMed ID: 11697844
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
Woloch C; Di Paolo A; Marouani H; Bocci G; Ciccolini J; Lacarelle B; Danesi R; Iliadis A
Curr Top Med Chem; 2012; 12(15):1713-9. PubMed ID: 22978343
[TBL] [Abstract][Full Text] [Related]
5. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Bocci G; Danesi R; Allegrini G; Innocenti F; Di Paolo A; Falcone A; Conte PF; Del Tacca M
Eur J Clin Pharmacol; 2002 Dec; 58(9):593-5. PubMed ID: 12602342
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
7. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
Katona C; Kralovánszky J; Rosta A; Pandi E; Fónyad G; Tóth K; Jeney A
Oncology; 1998; 55(5):468-74. PubMed ID: 9732227
[TBL] [Abstract][Full Text] [Related]
8. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.
Di Paolo A; Ibrahim T; Danesi R; Maltoni M; Vannozzi F; Flamini E; Zoli W; Amadori D; Del Tacca M
Ther Drug Monit; 2002 Oct; 24(5):588-93. PubMed ID: 12352929
[TBL] [Abstract][Full Text] [Related]
9. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.
Maring JG; van Kuilenburg AB; Haasjes J; Piersma H; Groen HJ; Uges DR; Van Gennip AH; De Vries EG
Br J Cancer; 2002 Apr; 86(7):1028-33. PubMed ID: 11953843
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
11. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.
Di Paolo A; Danesi R; Ciofi L; Vannozzi F; Bocci G; Lastella M; Amatori F; Martelloni BM; Ibrahim T; Amadori D; Falcone A; Del Tacca M
Ther Drug Monit; 2005 Jun; 27(3):362-8. PubMed ID: 15905808
[TBL] [Abstract][Full Text] [Related]
12. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
14. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
Dong QM; He YJ; Li S; Zhou ZM; Zhang L; Zhou ZW; Xia ZJ; Li YY
Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
Khor SP; Amyx H; Davis ST; Nelson D; Baccanari DP; Spector T
Cancer Chemother Pharmacol; 1997; 39(3):233-8. PubMed ID: 8996526
[TBL] [Abstract][Full Text] [Related]
16. Population study of dihydropyrimidine dehydrogenase in cancer patients.
Etienne MC; Lagrange JL; Dassonville O; Fleming R; Thyss A; Renée N; Schneider M; Demard F; Milano G
J Clin Oncol; 1994 Nov; 12(11):2248-53. PubMed ID: 7964939
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
Milano G; Chamorey AL
Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
[TBL] [Abstract][Full Text] [Related]
20. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.
van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Van Lenthe H; Bakker PJ; Richel DJ; Guchelaar HJ
Eur J Cancer; 2007 Jan; 43(2):459-65. PubMed ID: 17097873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
